Wagle, M
Eiring, A M
Wongchenko, M
Lu, S
Guan, Y
Wang, Y
Lackner, M
Amler, L
Hampton, G
Deininger, M W
O'Hare, T
Yan, Y
Article History
Received: 15 September 2015
Revised: 29 January 2016
Accepted: 18 February 2016
First Online: 8 March 2016
Competing interests
: Some of the authors are employees of Roche/Genentech. We used our in-house molecules, GDC-0941 and GDC-0973, as representative PI3K and MEK kinase inhibitors, respectively. These molecules have been published and are available from commercial sources. Furthermore, our findings should be applicable to similar inhibitors from other sources. The remaining authors declare no conflict of interest.